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BACKGROUND. Based on the activity of gemcitabine in heavily pretreated patients
with cutaneous T-cell lymphoma (CTCL), the objective of the current study was to
determine the role of gemcitabine in the treatment of patients with advanced,
untreated CTCL.
METHODS. Between June 2002 and February 2004, 32 untreated patients with
mycosis fungoides (MF) (n  26 patients); peripheral T-cell lymphoma, unspeci-
fied (PTCLU) with exclusive skin involvement (n  5 patients); and Sezary syn-
drome (SS) (n 1 patient) were enrolled in a 7-institution, Phase II trial and treated
with gemcitabine. This drug was given on Days 1, 8, and 15 of a 28-day schedule
at a dose of 1200 mg/m2 intravenously over 30 minutes for a total of 6 cycles.
RESULTS. Of the 32 patients studied, 7 (22%) achieved a complete response (CR)
and 17 (53%) achieved a partial response (PR), whereas the remaining 8 patients
showed no benefit from the treatment. Five of the CRs were confirmed histologi-
cally. The CR and PR rates were found to be the same for patients with MF and
PTCLU, respectively. The median duration of CR was 10 months (range, 4–22 mos).
Treatment appeared to be well tolerated; hematologic toxicity was mild and no
nausea/emesis or organ toxicity was noted.
CONCLUSIONS. The results of the current Phase II study demonstrate the activity of
gemcitabine as a single agent in untreated CTCL patients. Further studies using
gemcitabine in combination, either contemporary or sequentially, with other drugs
in patients with advanced stage, untreated CTCL are needed. Cancer 2005;104:
2437–41. © 2005 American Cancer Society.
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The term primary cutaneous lymphoma refers to cutaneous T-celllymphomas (CTCL) and cutaneous B-cell lymphomas that present in
the skin with no evidence of extracutaneous disease at the time of
diagnosis. Cutaneous lymphomas are the second most common group
of extranodal lymphomas, after gastrointestinal lymphomas.1,2
The CTCL spectrum includes mycosis fungoides (MF), which
represents approximately 80% of cases; erytrodermic expressions of
CTCL, including Sezary syndrome (SS), which represent 10–15% of
cases; and a variety of other peripheral T-cell lymphomas that arise in
the skin.3
The treatment of CTCL has been in a state of continual change
over the past few years as new therapies continue to emerge in the
search for more effective treatments. However, the prognosis of pa-
tients with CTCL remains dependent on their overall clinical stage of
disease (Ann Arbor Stage IA-IVBr) at the time of presentation as well
as their response to therapy. Past therapies have been limited by
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toxicity or a lack of consistently durable responses,
and to our knowledge few treatments to date have
been shown to actually alter survival, especially in
patients with late-stage disease. Even aggressive che-
motherapy has not been shown to improve overall
survival.4
Patients with disease limited to the skin, in the
form of patches and plaques, respond best to “skin
direct therapy” with topical agents including cortico-
steroids, nitrogen mustard, carmustine, and bexaro-
tene in a gel formulation (or, more recently, as an oral
formulation), as well as phototherapy with ultraviolet
B light, psoralen and ultraviolet A radiation therapy
(PUVA), or photodynamic therapy.5
Recently approved by the Food and Drug Admin-
istration (FDA), denileukin diftitox is the first of a
novel class of fusion toxin proteins and is selective for
interleukin-2R (CD25), targeting the malignant T-
cell clones in CTCL.6 More recent developments in the
treatment of CTCL include selective immunomodula-
tory agents and monoclonal antibodies.7,8
At the forefront of developing systemic chemo-
therapy, pegylated liposomal doxorubicin, pentosta-
tin, and gemcitabine appear to have the greatest po-
tential for success in CTCL therapy.9–14 Gemcitabine
(2,2-difluorodeoxycytidine) in particular is a pyrimi-
dine antimetabolite with structural similarities to cyt-
arabine; however, its pharmacology and mechanism
of action differ from other pyrimidine analogs in sev-
eral aspects. Gemcitabine serves as a better transport
substrate for uptake into the cells, is phosphorylated
more efficiently to the active gemcitabine triphos-
phate, inhibits elongation of the DNA chain through a
mechanism termed “masked chain termination,” and
competitively inhibits ribonucleotidyl reductase. The
result is impaired DNA synthesis and the induction of
apoptosis.
In the field of hematology, gemcitabine has been
demonstrated to be active in heavily pretreated pa-
tients with Hodgkin disease,15,16 as well as those with
aggressive and indolent non-Hodgkin lymphoma.17,18
The objective of the current study was to deter-
mine the role of gemcitabine in previously treated
(only local radiotherapy or PUVA therapy) or un-
treated patients with advanced MF and peripheral
T-cell lymphoma, unspecified, with skin involvement
(PTCLU).
MATERIALS AND METHODS
Between June 2002 and February 2004, 32 patients
with untreated MF, PTCLU, and SS were treated with
gemcitabine in 7 Italian institutions. Criteria for inclu-
sion in the study included a histologic diagnosis of
MF, SS, or PTCLU according to the Revised European–
American Lymphoma (REAL) classification2; the pres-
ence of measurable lesions; untreated disease or dis-
ease previously treated with local radiotherapy or
PUVA therapy at least 3 months before enrollment in
the protocol; isolated cutaneous involvement and le-
sions limited to a single (bulky) cutaneous region or
disseminated disease, involving at least 2 nonadjacent
regions; a performance status of 0–1 according to
ECOG score; normal cardiac, renal, and hepatic func-
tion; a negative pregnancy test for female patients,
and negative serology for the human immunodefi-
ciency virus, hepatitis B virus, and hepatitis C virus.
Disease extension was determined at the time of
diagnosis and at the end of treatment with complete
physical examination, including complete skin exam-
ination and determination of tumor size; laboratory
tests; computed tomography (CT) scanning of the
chest, abdomen, and pelvis; and bone marrow biopsy.
CT scanning and bone marrow biopsy were repeated
at the end of treatment only if they were positive at the
time of diagnosis. Response evaluation was performed
between 3–5 weeks after the last course of treatment.
During each subsequent course of gemcitabine ther-
apy, physical examination, laboratory tests, and grad-
ing of acute and subacute toxicity were evaluated and
adverse events were determined.
Patient Population
Detailed patient characteristics are listed in Table 1.
Twenty-six of 32 patients had a diagnosis of MF, 5
were diagnosed with PTCLU, and only 1 patient had
SS. All patients with MF were classified with T3 or T4,
TABLE 1
Characteristics of the Study Group
Characteristic
M:F ratio 22:10
Age in yrs
Median 58
Range 25–77
Histology
MF 26 (81%)
PTCLU 5 (16%)
SS 1 (3%)
Previous treatments (n  22 patients)
Radiotherapy 4
PUVA 10
PUVA plus local radiotherapy 8
TNM classification/Ann Arbor stage
MF (T3 or T4, N0,M0) 26
PTCLU (Stage IV, skin) 5
M:F: male-to-female; MF: mycosis fungoides; PTCLU: peripheral T-cell lymphoma, unspecified; SS:
Sezary syndrome; PUVA: psoralen and ultraviolet A radiation therapy.
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N0, M0 disease19 using the TNM classification for T-
cell lymphoma and patients with PTCLU were classi-
fied with Stage IV disease according to the Ann Arbor
staging system.20 The median age of the patients was
58 years (range, 25–77 yrs); 22 patients were male and
10 were female. Of the 32 patients studied, 4 had been
previously treated with local radiotherapy, 10 had re-
ceived previous PUVA therapy, and 8 had been treated
previously with PUVA and radiotherapy, whereas 10
patients had not received any previous treatment.
Treatment Protocol
Gemcitabine hydrochloride (Gemzar; Eli Lilly and
Company, Florence, Italy) was diluted in normal sa-
line and administered intravenously over the course of
30 minutes. Gemcitabine was given to all patients on
Days 1, 8, and 15 of a 28-day schedule at a dose of 1200
mg/m2 per day for a total of 6 cycles. All cycles were
delivered on an outpatient basis.
Response Evaluation
Tumor response was assessed by measuring the re-
duction in skin lesions on physical examination and
the reduction in lymph node infiltration by CT scan.
Response was defined according to previously re-
ported international criteria.21
Overall survival (OS) and progression-free survival
(PFS) curves were calculated according to the method
of Kaplan and Meier.22 Toxicity was evaluated through
weekly physical examination, complete blood counts,
and chemistry (biochemical) profiles. All signs, symp-
toms, or laboratory abnormalities were defined using
the World Health Organization criteria for toxicity.
RESULTS
Treatment Outcome
Clinical results are summarized in Table 2. The overall
response rate (CR  PR) was 75 % (24 of 32 patients).
The CR and PR rates were 22% (7 of 32 patients) and
53% (17 of 32 patients), respectively. Patients with MF
had a CR rate of 23% (6 of 26 patients) and a PR rate of
50% (13 of 26 patients). Conversely, patients with PT-
CLU had a CR rate of 20% (1 of 5 patients) and a PR
rate of 80% (4 of 5 patients). The one patient with a
diagnosis of SS had no response after therapy.
Of the 7 patients who achieved a CR, 3 were still in
disease remission after a median follow-up of 10
months (range, 4–22 mos).
Figure 1 shows the PFS curve of all patients who
were treated with gemcitabine. The median PFS was 10
months (range, 1–22 mos). Figure 2 shows the OS curve.
The median OS was 19 months (range, 8–32 mos).
Treatment Toxicity
Gemcitabine was generally well tolerated (Table 3).
With regard to hematologic toxicity, 37.5% (12 of 32
TABLE 2
Treatment Outcome
Total
(n  32
patients)
MF
(n  26
patients)
PTCLU
(n  5
patients)
SS
(n  1
patient)
CR 7 (22%) 6 (23%) 1 (20%) —
PR 17 (53%) 13 (50%) 4 (80%) —
No response 8 (25%) 7 (27%) — 1 (100%)
CR  PR 24 (75%) 19 (73%) 5 (100%) —
MF: mycosis fungoides; PTCLU: peripheral T-cell lymphoma, unspecified; SS: Sezary syndrome; CR:
complete response; PR: partial response.
FIGURE 1. Progression-free survival curve of all responding patients.
FIGURE 2. Overall survival curve of the entire study population.
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patients) had WHO Grade 1-2 anemia and 3% (1 of 32
patients) had WHO Grade 3 anemia. No patients were
found to have WHO Grade 4 anemia. Grade 3-4
thrombocytopenia and neutropenia were observed in
12% (4 of 32 patients) and 16% (5 of 32 patients),
respectively. With regard to nonhematological toxic-
ity, the most significant toxicity was hepatic toxicity.
Grade 1-2-3 hepatic toxicity was observed in 37% of
patients (12 of 32 patients) and Grade 4 hepatic tox-
icity was reported in 3% of patients (1 of 3 patients).
However, the hepatic injury was reversible in all cases.
Hair loss was mild to moderate, and no patients ex-
perienced complete alopecia. No nausea and emesis
were reported. There were no instances of renal or
cardiac toxicity. No patients died of complications
related to gemcitabine.
DISCUSSION
T-cell malignancies are reported to comprise approx-
imately 15% of all hematologic neoplasms diagnosed
in Western countries. Although more information
concerning the pathobiology and immunology of
these tumors has become available, there is consider-
able debate regarding their clinical behavior and re-
sponse to conventional treatment. Several authors
have reported satisfactory results using purine analogs
in the treatment of different types of recurrent or
refractory T-cell malignancies.14,23,24
Kurzrock et al. reported results using pentostatin
in 28 CTCL patients; the overall response rate was 71%
and the most common side effects were granulocyto-
penia, nausea, and nonneutropenic fever.25 Other
studies examining cladribine, fludarabine, and gem-
citabine as single agents in pretreated CTCL patients
reported an overall response rate of 24–47% for
cladribine and fludarabine.23,24 The most interesting
data were obtained for gemcitabine. Sallah et al. re-
ported an overall response rate of 60% with a 20% CR
rate; our previous reports demonstrated a 70% overall
response rate with a CR rate of 11%.13,14
These findings led us to conclude that gemcitab-
ine has the highest activity with acceptable toxicity in
previously treated patients with CTCL. For this reason,
we decided to use gemcitabine as the frontline treat-
ment of CTCL to evaluate tumor response, as well as
the safety and duration of response.
In the current study, we obtained an overall re-
sponse rate of 75%, with a CR rate of 22% and a PR rate
of 53%. Nine of 32 patients had a follow-up period of
at least 18 months; at the time of last follow-up, 8 of 9
patients were alive (89%) and 1 patient remained in
complete disease remission.
Gemcitabine as a single agent has proven to be
effective in untreated patients with CTCL; moreover,
its modest toxicity profile and easy schedule of admin-
istration make it an ideal agent for frontline use. Re-
cent studies have demonstrated the efficacy and safety
of gemcitabine, cisplatin, and steroids in the treat-
ment of patients with recurrent or refractory Hodgkin
disease and non-Hodgkin lymphoma.26,27 Gemcitab-
ine also has been tested in association with oxaliplatin
in patients with recurrent and refractory lymphoma.28
This combination also has been shown to be effective
in heavily pretreated patients with T-cell non-Hodgkin
lymphoma. In future trials, it will be interesting to test
these gemcitabine-containing regimens in patients
with CTCL. In particular, based on preliminary data
from the study of alemtuzumab in CTCL patients, we
currently are planning a Phase II trial in untreated
patients, comprised of an initial phase with gemcitab-
ine and a sequential consolidation phase with low-
dose alemtuzumab.
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